Skip to content

Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix

The Value of Complementary Right-sided Hemicolectomy for Pediatric Patients With High-risk Neuroendocrine Tumors (NETs) of the Appendix; Towards the Development of an (Inter-) National Consensus Guideline for the Pediatric Population.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05919758
Acronym
NETkids
Enrollment
1000
Registered
2023-06-26
Start date
2023-05-01
Completion date
2025-06-30
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appendix Cancer, Neoplasms

Brief summary

The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children. .

Detailed description

Aim Current guidelines recommend complementary right-sided hemicolectomy for high-risk (pT2(with risk factors)/pT3) neuro-endocrine tumors (NET) of the appendix (based on adult studies). In contrast to adults, high-risk NET of the appendix in children seems to be a relatively benign disease with high disease-free survival (100% versus 70-80% in adults), but high quality data are lacking. Therefore these recommendations are now being questioned. We aim to investigate the value of complementary right-sided hemicolectomy for children with high-risk NET of the appendix. Ultimately leading to the development of a consensus guideline and solid information for patients/parents. Plan of investigation In order to generate big data, an international historical cohort study is planned to compare complementary right-sided hemicolectomy with appendectomy alone for children with high-risk NET of the appendix. Results will be CONFIDENTIAL used by an international expert group to formulate treatment recommendations. Subsequently, these recommendations will be tested in an international Delphi study in order to develop a consensus guideline on the treatment of pediatric high-risk NET of the appendix. Expected results The cohort study will generate high quality information on overall/disease-free survival, recurrence, complications, costs, and hr-QoL. Recommendations made will be tested in a Delphi study; not only on the beneficial value of complementary right-sided hemicolectomy, but also on follow-up protocols and preoperative work-up. Ultimately, an international consensus guideline that redefines low-risk and high-risk NET of the appendix will be developed, leading to global de-escalation and uniformity of treatment. Relevance for childhood cancer Results are relevant for pediatric oncologists/surgeons/gastro-enterologists across the world, as redefining low-risk and high-risk patient groups, will lead to de-escalation of treatment. Furthermore, QoL of child and parents can be improved by reducing exposure to complications after complementary right-sided hemicolectomy, and by reducing the fear of recurrence by obtaining high-quality data to accurately inform patients and parents.

Interventions

None listed

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years

Inclusion criteria

* All patients that were treated for an appendiceal NET before the age of 18 years old * Time period: 1990-2020

Exclusion criteria

* Other appendiceal malignancies/tumours, for example: * goblet cell carcinoma * adenocarcinoma * neuroendocrine carcinoma

Design outcomes

Primary

MeasureTime frameDescription
Disease free survival ratecross-sectional design. follow-up will be done in 2023/2024defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose
Recurrence ratecross-sectional design. follow-up will be done in 2023/2024defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period

Secondary

MeasureTime frameDescription
Number of hospital readmission for complications related to treatment of NETcross-sectional design. follow-up will be done in 2023/2024see title
Length of hospital staycross-sectional design. follow-up will be done in 2023/2024initial and total length of stay
Overall survival ratecross-sectional design. follow-up will be done in 2023/2024defined as alive at telephone follow-up performed for this study purpose
Number of outpatient check-ups(regular visits / telephone call) for follow-up of NETcross-sectional design. follow-up will be done in 2023/2024see title
Health related Quality of Life at follow-up moment for this studycross-sectional design. follow-up will be done in 2023/2024measured by the PedsQL(generic)
number of imaging studies performed for follow-up of NETcross-sectional design. follow-up will be done in 2023/2024ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), octreotide scintigraphy, PET-CT
Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo.cross-sectional design. follow-up will be done in 2023/2024Complications include, but are not limited to: * Intra-abdominal abscess, defined as a radiologically confirmed accumulation of purulent fluid in a walled-off space within the abdominal cavity. * (Adhesive) bowel obstruction requiring readmission (diagnosis based on clinical signs and symptoms such as a history of constipation, nausea, vomiting and distended abdomen) * Superficial Surgical Site Infection, as defined by the CDC criteria. (see table 1.) * Deep Surgical Site Infection, as defined by the CDC criteria.

Countries

Netherlands

Contacts

Primary ContactRamon R Gorter, MD PhD
rr.gorter@amsterdamumc.nl0205669111
Backup ContactMartine F Raphael, MD PhD
m.raphael@amsterdamumc.nl0205669111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026